A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc.
Institut Curie
Elios Therapeutics, LLC
GlaxoSmithKline
Thomas Jefferson University
Jazz Pharmaceuticals
Boehringer Ingelheim
InflaRx GmbH
Strata Oncology
Indiana University
Albert Einstein College of Medicine
University of Wisconsin, Madison
Hoosier Cancer Research Network
Big Ten Cancer Research Consortium
RAPT Therapeutics, Inc.
M.D. Anderson Cancer Center
Sir Mortimer B. Davis - Jewish General Hospital
Karyopharm Therapeutics Inc
Yale University
Incyte Corporation
Vanderbilt-Ingram Cancer Center
Stanford University
Oslo University Hospital
Medstar Health Research Institute
Burzynski Research Institute
University of California, San Francisco
University of California, San Francisco
Centre Oscar Lambret
McGill University
Oslo University Hospital
Novartis
Esanex Inc.
Midwestern Regional Medical Center
University of Pittsburgh
Burzynski Research Institute
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
Icahn School of Medicine at Mount Sinai
GERCOR - Multidisciplinary Oncology Cooperative Group
Fox Chase Cancer Center
Beth Israel Deaconess Medical Center
GlaxoSmithKline
University of Pittsburgh
New Mexico Cancer Research Alliance
University of Zurich
AstraZeneca
Duke University
National University Hospital, Singapore
Cambridge University Hospitals NHS Foundation Trust
Advanced Viral Research Corp